FI112168B - Menetelmä anti-D-immunoglobuliini G-konsentraatin valmistamiseksi - Google Patents

Menetelmä anti-D-immunoglobuliini G-konsentraatin valmistamiseksi Download PDF

Info

Publication number
FI112168B
FI112168B FI946103A FI946103A FI112168B FI 112168 B FI112168 B FI 112168B FI 946103 A FI946103 A FI 946103A FI 946103 A FI946103 A FI 946103A FI 112168 B FI112168 B FI 112168B
Authority
FI
Finland
Prior art keywords
igg
plasma
adsorbent
rhesus
fraction
Prior art date
Application number
FI946103A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI946103L (fi
FI946103A0 (fi
Inventor
Peter Lerch
Gerhard Hodler
Martin Stucki
Original Assignee
Zlb Bioplasma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8215103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI112168(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zlb Bioplasma Ag filed Critical Zlb Bioplasma Ag
Publication of FI946103A0 publication Critical patent/FI946103A0/fi
Publication of FI946103L publication Critical patent/FI946103L/fi
Application granted granted Critical
Publication of FI112168B publication Critical patent/FI112168B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI946103A 1993-12-27 1994-12-27 Menetelmä anti-D-immunoglobuliini G-konsentraatin valmistamiseksi FI112168B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93810912 1993-12-27
EP93810912A EP0659767B2 (de) 1993-12-27 1993-12-27 Verfahren zur Herstellung eines Konzentrates von Anti-D-Immunoglobulin G und pharmazeutische Zusammensetzung, die dieses enthält

Publications (3)

Publication Number Publication Date
FI946103A0 FI946103A0 (fi) 1994-12-27
FI946103L FI946103L (fi) 1995-06-28
FI112168B true FI112168B (fi) 2003-11-14

Family

ID=8215103

Family Applications (1)

Application Number Title Priority Date Filing Date
FI946103A FI112168B (fi) 1993-12-27 1994-12-27 Menetelmä anti-D-immunoglobuliini G-konsentraatin valmistamiseksi

Country Status (20)

Country Link
US (1) US5593675A (da)
EP (1) EP0659767B2 (da)
JP (1) JP2926463B2 (da)
KR (1) KR100368563B1 (da)
AT (1) ATE175979T1 (da)
AU (1) AU682243B2 (da)
CA (1) CA2138921C (da)
CZ (1) CZ286271B6 (da)
DE (1) DE59309332D1 (da)
DK (1) DK0659767T4 (da)
ES (1) ES2129076T5 (da)
FI (1) FI112168B (da)
GR (1) GR3029817T3 (da)
HU (1) HU216864B (da)
NO (1) NO315331B1 (da)
NZ (1) NZ278057A (da)
PL (1) PL180358B1 (da)
SI (1) SI9420008B (da)
TW (1) TW311884B (da)
WO (1) WO1995018155A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ507557A (en) * 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
DK2270044T3 (da) * 1998-06-09 2015-01-26 Csl Behring Ag Flydende immunglobulin G (IgG) produkt
DE19923027C2 (de) * 1999-05-19 2002-09-19 Aventis Behring Gmbh Verfahren zur Inaktivierung von Viren
US6475749B1 (en) * 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
SE0001128D0 (sv) * 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
CA2458750C (en) 2004-02-23 2012-02-07 Bayer Inc. Isoolefin-diolefin production process and apparatus therefor
EP1885755A4 (en) * 2005-05-05 2009-07-29 Univ Duke CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
TWI320788B (en) 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
SI2061803T2 (sl) * 2006-08-28 2023-01-31 Ares Trading S.A. Postopek za čiščenje proteinov, ki vsebujejo FC
WO2008025747A1 (en) * 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
IT1397061B1 (it) * 2009-12-28 2012-12-28 Kedrion Spa Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale.
WO2011095543A1 (en) 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
US20120076779A1 (en) * 2010-09-17 2012-03-29 Baxter Healthcare S.A. STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
SG11201400233TA (en) * 2011-08-26 2014-08-28 Baxter Int Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
KR101917196B1 (ko) * 2014-03-11 2018-11-09 주식회사 녹십자홀딩스 면역글로불린의 정제방법
KR101917197B1 (ko) * 2014-03-11 2018-11-09 주식회사 녹십자홀딩스 면역글로불린의 정제방법
ES2988823T3 (es) 2014-12-03 2024-11-21 Csl Behring Ag Producto farmacéutico con mayor estabilidad que comprende inmunoglobulinas
EP3810649A1 (en) * 2018-06-22 2021-04-28 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
EP4349859A1 (en) * 2023-01-27 2024-04-10 CSL Behring AG Method to purify anti-d immunoglobulin g from plasma
EP4655316A1 (en) * 2023-01-27 2025-12-03 CSL Behring AG Method for reducing protease activity in a solution comprising anti-d immunoglobulin g

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869436A (en) * 1971-06-01 1975-03-04 Statens Bakteriologiska Lab Method for fractionating plasma proteins using peg and ion-exchangers
EP0085747B2 (de) * 1982-02-08 1990-05-30 Schweizerisches Serum- und Impfinstitut und Institut zur Erforschung der Infektionskrankheiten Intravenös verabreichbares humanes Immunglobulin und Verfahren zu dessen Herstellung
US4434093A (en) * 1982-07-26 1984-02-28 Ortho Diagnostic Systems Inc. Methods for preparation of HBs Ag free gamma globulins
DE3640513A1 (de) * 1986-11-27 1988-06-09 Biotest Pharma Gmbh Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins

Also Published As

Publication number Publication date
HU9502514D0 (en) 1995-11-28
JP2926463B2 (ja) 1999-07-28
CA2138921A1 (en) 1995-06-28
CA2138921C (en) 2004-11-02
PL180358B1 (pl) 2001-01-31
EP0659767B2 (de) 2002-11-06
WO1995018155A1 (en) 1995-07-06
SI9420008B (sl) 1998-06-30
HU216864B (hu) 1999-09-28
HUT73376A (en) 1996-07-29
GR3029817T3 (en) 1999-06-30
NO945032D0 (no) 1994-12-23
NZ278057A (en) 1997-03-24
FI946103L (fi) 1995-06-28
JPH07206708A (ja) 1995-08-08
EP0659767B1 (de) 1999-01-20
CZ286271B6 (cs) 2000-03-15
CZ249295A3 (en) 1996-01-17
EP0659767A1 (de) 1995-06-28
TW311884B (da) 1997-08-01
NO315331B1 (no) 2003-08-18
DE59309332D1 (de) 1999-03-04
FI946103A0 (fi) 1994-12-27
DK0659767T4 (da) 2003-02-10
ES2129076T3 (es) 1999-06-01
US5593675A (en) 1997-01-14
AU682243B2 (en) 1997-09-25
NO945032L (no) 1995-06-28
DK0659767T3 (da) 1999-09-13
ES2129076T5 (es) 2003-05-16
AU1414395A (en) 1995-07-17
KR960701098A (ko) 1996-02-24
SI9420008A (en) 1996-02-29
ATE175979T1 (de) 1999-02-15
KR100368563B1 (ko) 2003-04-03
PL310435A1 (en) 1995-12-11

Similar Documents

Publication Publication Date Title
FI112168B (fi) Menetelmä anti-D-immunoglobuliini G-konsentraatin valmistamiseksi
US5886154A (en) Chromatographic method for high yield purification and viral inactivation of antibodies
AU731950B2 (en) Concentrated antibody preparation
US6955917B2 (en) Chromatographic method for high yield purification and viral inactivation of antibodies
Stiehm et al. Preparation and use of therapeutic antibodies primarily of human origin
KR100236762B1 (ko) 사람 혈장의 분별 동안에 생성된 분별물로부터 면역글로불린을 회수하는 방법
JPH0365327B2 (da)
Hässig Intravenous immunoglobulins: pharmacological aspects and therapeutic use
EP0973549A2 (en) Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties
HK1009277B (en) Process to prepare an anti-d immunoglobulin g concentrate and pharmaceutical compositions comprising it
HK1009277A1 (en) Process to prepare an anti-d immunoglobulin g concentrate and pharmaceutical compositions comprising it
Yap Humoral Functions of Immunoglobulin: Relationship to Purification Technology of Intravenous Immunoglobulin
MXPA98009645A (en) Concentrated preparation of anticuer

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: ZLB BEHRING AG

Free format text: ZLB BEHRING AG

PC Transfer of assignment of patent

Owner name: CSL BEHRING AG

Free format text: CSL BEHRING AG

MM Patent lapsed